Total Fumarates (Tecfidera + Vumerity) revenues were $400.7 million in the quarter, down 10.5% year over year. Tysabri sales declined 4.9% year over year to $464.7 million, hurt by increased competition and pricing pressure. Tysabri's sales beat the Zacks Consensus Estimate of $444 million and our estimate of $448 million. Combined interferon revenues (Avonex and Plegridy) in the quarter were $280.0 million, down 9.6%, hurt by a continued shift from the injectable platform to oral or high-efficacy therapies.